ResApp Health Limited announced the establishment of a COVID-19 Scientific Advisory Board. The COVID-19 SAB will provide scientific and clinical advice to ResApp's COVID-19 programs which are focused on delivering COVID-19 screening and disease management tools. The first appointees to the COVID-19 SAB are four leading clinicians from the United States and Australia: Professor Elizabeth Talbot is Professor of Medicine in the Infectious Diseases and International Health Section at the Geisel School of Medicine, at Dartmouth (USA). Additionally, she is the Deputy State Epidemiologist for the State of New Hampshire in leadership for COVID-19 response, Director of International Health Clinic at Dartmouth, and a tuberculosis Technical Consultant for the Bill & Melinda Gates Medical Research Institute. Previously Professor Talbot worked for the Centers for Disease Control and Prevention (CDC) and engaged in clinician education in West Africa during the 2014 Ebola outbreak. Professor Catherine Bennett is the inaugural Chair in Epidemiology and head of Deakin Epidemiology within the Institute for Health Transformation at Deakin University. This follows more than eight years with the University of Melbourne where she was Associate Professor in Epidemiology and Director of Population Health Practice in the Melbourne School of Population and Global Health. Her expertise is population-based research into community transmission, and she is actively engaged in multi-country COVID-19 research, and regularly appears in the media internationally providing expert commentary on the COVID-19 pandemic. Professor Bennett has a distinguished career in public health practice, research, academic governance and teaching. Associate Professor Mark Howard is the Director of the Victorian Respiratory Support Service and Institute for Breathing and Sleep at Austin Health. He is a specialist physician in respiratory and sleep medicine. He is Clinical Associate Professor at The University of Melbourne and Adjunct Associate Professor at Monash University. Associate Professor Howard has been actively engaged in managing COVID-19 patients, establishing a post-acute COVID-19 clinic at Austin Health and is widely published on COVID-19 including work with the US CDC on risk factors and public compliance with management strategies. Associate Professor Paul Porter is a current ResApp Scientific Advisor and has been the Principal Investigator on several of ResApp's foundational clinical trials. He is a Consultant Paediatrician with subspecialty training in Paediatric Emergency Medicine. He is the Chair of the Ramsay Health Care Group Human Research and Ethics Committee (Western and South Australia) and is the scientific lead for the Partnership in Heath Intelligence research group in Perth, Western Australia. Associate Professor Porter is a director of Valo Therapeutics, a Finnish immunotherapy company that is developing a pan-coronavirus vaccine using peptide coated non-replicating adenoviral vectors targeting conserved structural proteins.